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Notch regulates BMP responsiveness and lateral
branching in vessel networks via SMAD6
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Functional blood vessel growth depends on generation of distinct but coordinated responses
from endothelial cells. Bone morphogenetic proteins (BMP), part of the TGFb superfamily,
bind receptors to induce phosphorylation and nuclear translocation of SMAD transcription
factors (R-SMAD1/5/8) and regulate vessel growth. However, SMAD1/5/8 signalling results
in both pro- and anti-angiogenic outputs, highlighting a poor understanding of the
complexities of BMP signalling in the vasculature. Here we show that BMP6 and BMP2
ligands are pro-angiogenic in vitro and in vivo, and that lateral vessel branching requires
threshold levels of R-SMAD phosphorylation. Endothelial cell responsiveness to these
pro-angiogenic BMP ligands is regulated by Notch status and Notch sets responsiveness by
regulating a cell-intrinsic BMP inhibitor, SMAD6, which affects BMP responses upstream
of target gene expression. Thus, we reveal a paradigm for Notch-dependent regulation of
angiogenesis: Notch regulates SMAD6 expression to affect BMP responsiveness of
endothelial cells and new vessel branch formation.
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B
lood vessel networks expand via endothelial cell (EC)
sprouting, migration, anastomosis and lumenization to
form new conduits, a process called sprouting
angiogenesis1. Heterogeneous yet coordinated responses to
pro-angiogenic signals are essential for proper angiogenesis and
for subsequent maintenance of a functional vasculature2–6.
Numerous signalling pathways integrate to provide this
heterogeneity in ways that are not completely understood5,7,8.
Bone morphogenetic protein (BMP) signalling is essential
to the proper form and function of blood vessels8–14. BMPs
belong to the tranforming growth factor-b superfamily of
secreted growth factors and they signal through cell-surface
heterotetramers of type II and type I serine/threonine kinase
receptors15,16. Phosphorylation of type I receptors by type II
receptors induces phosphorylation of the receptor-associated
SMADs 1, 5 and 8 (R-SMADs 1/5/8). R-SMAD phosphorylation
induces association with SMAD4 and this complex translocates to
the nucleus, to regulate expression of target genes. SMAD6 is an
inhibitory SMAD that competitively binds type I receptors or
SMAD4 to inhibit SMAD1/5/8 phosphorylation or nuclear
translocation, respectively, and downregulate BMP signalling17,18.
Recent studies highlight novel roles for BMPs during
angiogenesis8–14. Global genetic deletion of SMAD5 in mice led
to multiple angiogenesis defects during embryogenesis19.
EC-selective deletion of SMAD1 and SMAD5 severely impaired
angiogenesis, resulting in defective yolk sac and cranial
vasculature, and SMAD1/5 double knockout EC displayed
reduced proliferation and migration, implicating BMP signalling
in cellular processes essential to angiogenesis8. In zebrafish,
Bmp2b is a venous-specific pro-angiogenic signal that promotes
Vegfaa-independent sprouting from the posterior cardinal vein9.
The type I BMP receptor ALK1 is either anti-angiogenic or
pro-angiogenic when inhibited by Fc-conjugation or a highly
specific blocking antibody, respectively10,13. These data suggest
that the angiogenic activity of BMP ligands is context dependent.
EC differentially respond to BMP signalling9, but how BMP
responsiveness is set remains largely unknown. Therefore,
we sought to identify a mechanism by which EC intrinsically
regulate the magnitude of their responses to BMP ligands.
Previous studies indicated that BMP6 and BMP2 can be
pro-angiogenic8,9,20. Here we show that these ligands are
pro-angiogenic, and that lateral vessel branching requires
threshold levels of R-SMAD phosphorylation. EC
responsiveness to pro-angiogenic BMP ligands is regulated by
Notch status. Notch sets responsiveness by regulating the
cell-intrinsic BMP inhibitor, SMAD6 and SMAD6 affects BMP
responses upstream of target gene expression, revealing a new
paradigm for Notch-dependent regulation of angiogenesis.
Results
BMP2 and BMP6 promote lateral vessel branching. We first
determined the effects of BMP6 and BMP2 on vessel branching in
a three-dimensional (3D) sprouting angiogenesis assay21 using
human umbilical vein endothelial cells (HUVEC). Addition of
exogenous BMP6 or BMP2 significantly increased both branching
frequency and branch angle compared with controls (Fig. 1a–d
and Supplementary Fig. 1a–d). Exogenous BMP2 had a similar
effect on branching frequency in mouse embryonic stem (ES)
cell-derived vessels (Supplementary Fig. 1e–g). Consistent with a
more highly branched phenotype, both ligands increased the
percentage of nuclei in the tip position of growing HUVEC
sprouts (Fig. 1e–g and Supplementary Fig. 1h–j). Moreover,
the BMP-induced branching phenotype was remarkably
well- organized, in contrast to the effects of elevated vascular
endothelial growth factor (VEGF)-A signalling, which often lead
to gross dysmorphogenesis22,23. Thus, BMP6 and BMP2 are
pro-angiogenic and increase vascular density by inducing new
branch formation. Furthermore, the increased branch angles lead
to lateralization of the branching pattern and suggest that
pro-angiogenic BMP signalling tunes vessel branching between a
‘bush-like’ and a ‘bamboo-like’ vessel pattern, in a ligand-
dependent manner.
We hypothesized that BMP-induced branching depended on
EC sprouting in response to activation and nuclear localization of
phosphorylated SMADs 1 and 5 (pSMAD1/5). We examined
levels of nuclear pSMAD1/5 in EC during sprouting angiogenesis
and found a striking inverse correlation between the distance of
nuclei from the sprout tip and intensity of nuclear pSMAD1/5
staining (Fig. 1h,j,m). Thus, EC with the highest levels of BMP
signalling were more likely to be in the tip cell position. As
expected, short-term BMP6 treatment significantly increased
overall nuclear pSMAD1/5 levels compared with controls
(Fig. 1i–k and Supplementary Fig. 1k). However, although acute
BMP6 exposure significantly increased the average nuclear
pSMAD1/5 levels in stalk cells, it had only a modest and
nonsignificant effect in tip cells (Fig. 1l), suggesting that EC at
sprout tips have maximal BMP pathway activation. In fact, stalk
EC in BMP6-treated sprouts had average nuclear pSMAD1/5
levels comparable to levels in tip EC of controls (Fig. 1l),
suggesting that BMP signalling increases vessel branching by
inducing additional tip cells from the pool of stalk cells. This idea
is also consistent with the finding that stalk cells, even after BMP
stimulation, retain extensive heterogeneity in nuclear pSMAD1/5
levels and their pSMAD1/5 levels do not as strongly correlate
with position in the sprout as controls (Fig. 1l,m).
To verify the necessity of SMAD1/5 for lateral branch
formation, we reduced the levels of each protein via small
interference RNAs (siRNAs) and analysed effects on sprouting.
Reduction of either SMAD1 or SMAD5 (Supplementary Figs 1l,m
and 5b) reduced BMP6-induced lateral branching. Although
SMAD1/5 signalling has also been implicated in stalk
cell maintenance5, this effect is thought to be downstream
of BMP9 engagement with complexes that include the type I
receptor ALK1 and induce vascular quiescence13,24,25. To
determine whether ALK1 signalling contributes to the effects
we observed, we reduced ALK1 levels via siRNA and found
no effect on BMP6-dependent increases in lateral branching
(Supplementary Figs 1n and 5b), suggesting that BMP6-induced
branching occurs independently of BMP9/ALK1 signalling. Thus,
pSMAD1/5 is required to mediate the pro-angiogenic effects of
BMP6 in EC independent of effects from ALK1 signalling. Taken
together, these data suggest that BMP-dependent lateral vessel
branching depends on EC that are ‘tunable’ and have an innate
set point of BMP responsiveness. For each EC, this innate
responsiveness sets a ligand threshold required to produce
sufficient pro-angiogenic pSMAD1/5 signalling and provoke an
EC response. In this scenario, short-term BMP6 treatment
increases the number of EC that achieve the threshold and are
capable of responding, leading to additional lateral branching.
Notch sets EC BMP responsiveness. If BMP responsiveness is
innate to EC, then factors that set this responsiveness and the
extent of R-SMAD phosphorylation are predicted to profoundly
affect BMP-dependent vascular architecture. Notch signals via its
intracellular domain (NICD) and this signalling represses the
tip cell phenotype and supports a non-branching stalk cell
phenotype26–29. Although recent work describes Notch-BMP
pathway crosstalk at the level of target gene expression8,13,30,31,
it is not clear whether Notch signalling alters the responsiveness
of EC to BMP via effects on upstream BMP pathway components.
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In the developing zebrafish, venous EC are BMP sensitive and
form ectopic sprouts after heat-shock induction of Bmp2b,
whereas intersegmental vessels (ISVs) are relatively unresponsive
at 24–48 hpf (ref. 9). To investigate regulators of BMP
responsiveness in this model, we used Tg(Tp1bglob:eGFP)
(Notch reporter) zebrafish embryos and asked how Notch
activity and BMP sensitivity align in the vasculature. Notch
reporter activity was strong in the dorsal aorta (DA) and ISVs,
consistent with other reports32,33, and these vessels do not
respond to ectopic BMP ligand9; however, the reporter signal was
undetectable in the BMP-responsive caudal vein plexus (CVP)
(Fig. 2a,b). To determine whether Notch influences BMP
responsiveness, we induced Notch signalling via heat-shock
induction of NICD. As we have described, ectopic induction of
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Figure 1 | BMP signalling promotes lateral branching of angiogenic sprouts. (a,b) HUVEC 3D sprouting assay with BMP6, representative of three
independent experiments, stained with phalloidin (actin) and depth encoded. (c,d) Quantification of (c) branches per mm (n¼ 7 control and 10 BMP6
beads) and (d) branch angle (n¼43 control and 133 BMP6 angles). Error bars, mean±95% confidence interval (CI). **Pr0.01; ***Pr0.001 by Student’s
t-test. (e,f) Sprouting HUVEC visualized with phalloidin (actin) and DRAQ7 (DNA). (g) Tip nuclei/total nuclei per field, representative of three independent
experiments (n¼ 9 control and 7 BMP6 sprouts). Error bars, mean±95% CI. **Pr0.01 by Student’s t-test. (h–k) HUVEC 3D sprouting assay 6 h
post-BMP6 treatment, visualized for nuclear pSMAD1/5, phalloidin (actin) and DRAQ7 (DNA). Images are three-channel compressed z-stacks (h,i) or
single-channel compressed z-stack heat maps of pSMAD1/5 staining intensity (j,k). Scale bar, 50mm. (l) Quantification of mean pSMAD1/5 fluorescence
intensity per nucleus, representative of 2 independent experiments (n¼ 13 control tip, 50 control stalk, 15 BMP6 tip, and 58 BMP6 stalk EC). Error bars,
mean±95% CI. NS, not significant; ***Pr0.001 and ****Pr0.0001 by one-way analysis of variance with Tukey’s post-hoc test. (m) Best-fit correlation
(solid line) with 95% CI intervals (filled areas) of indicated parameters. *Pr0.05 by linear regression.
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Bmp2b led to excessive sprouting from the CVP (Fig. 2c,e)9.
However, concomitant induction of Bmp2b and NICD
significantly reduced the frequency of CVP sprouts, suggesting
that ectopic Notch signalling dampens the sensitivity of EC to
BMPs (Fig. 2d,e). Conversely, to determine whether arterial EC
could be sensitized to Bmp2b overexpression, we blocked Notch
signalling by treatment with N-[2S-(3,5-difluorophenyl)acetyl]-L-
alanyl-2-phenyl-1,1-dimethylethyl ester-glycine (DAPT), a
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Figure 2 | Notch regulates BMP responsiveness. (a,b) Lateral view of vessel-specific (a) or Notch-activated (b) GFP expression in 28 hpf fish embryos.
Scale bar, 50mm. (c,d) Depth-encoded lateral view of44hpf fish embryos heat-shocked at 26 hpf. Scale bar, 50mm. (c) Tg(hsp70l:bmp2b) embryos
overexpress Bmp2b; (d) Tg(hsp70l:bmp2b);Tg(UAS:NICD); Tg(hsp70l:gal4) overexpress both Bmp2b and NICD. (e) Quantification of ectopic venous sprouts,
representative of two independent experiments. Data points, individual embryos (n¼ 12 WT, 11 Tg(hsp70l:Gal4);Tg(UAS:NICD), 9 Tg(hsp70l:bmp2b),
13 compound transgenics). Error bars, mean±95% CI. ****Pr0.0001 by one-way analysis of variance (ANOVA), with Tukey’s post-hoc test.
(f–k) Depth-encoded compressed z-stack lateral views of 44 hpf embryos heat shocked at 26 hpf and treated with vehicle (f–h) or DAPT (i–k) from 10 hpf,
representative of three independent experiments. (f,i) WT embryos; (g,j) Tg(hsp70l:bmp2b) embryos with ectopic venous z-slices removed to visualize
intersegmental arteries; (h,k) Tg(hsp70l:bmp2b) embryos. (l) quantification of ectopic arterial sprouts. Data points, individual embryos (n¼ 27
WT/dimethyl sulfoxide (DMSO), 26 Bmp2b/DMSO, 23 WT/DAPT and 26 Bmp2b/DAPT). Error bars, mean±95% CI. *Pr0.05, **Pr0.01 and
****Pr0.0001 by Kruskal–Wallis with Dunn’s post-hoc test. DA, dorsal aorta; DV, dorsal vein; ISV, intersegmental vessel; VV, ventral vein. (m) BMP6
twofold dose–response curve (indicated on x axis) in HUVEC after Notch activation (Dll4-Fc, red line) versus control (IgG-Fc, green line), representative of
two independent experiments. Data are four-parameter best-fit curves (solid lines) ±95% confidence bands (filled areas). *Pr0.05 by nonlinear
regression. Quantification (n) and panels (o) of nuclear pSMAD1/5 expression in individual HUVEC with indicated conditions, representative of two
independent experiments. Yellow arrow, EC expressing FLAG-NICD. Scale bar, 10mm. Error bars, mean±s.e.m. *Pr0.05 and ****P¼0.0001 by one-way
ANOVA with Tukey’s post-hoc test.
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g-secretase inhibitor that prevents cleavage and release of NICD.
Bmp2b induction induced a low level of ectopic vessels from
arterial EC (Fig. 2f–h,l) and DAPT treatment alone induced some
ectopic arterial angiogenesis, consistent with previous reports
(Fig. 2i,l)5,27. However, Notch inhibition combined with Bmp2b
induction resulted in a significantly higher frequency of ectopic
arteries compared with either manipulation alone (Fig. 2j–l).
These results indicate that Notch is an intrinsic regulator of the
magnitude of the BMP response in EC in vivo.
To quantitatively determine the impact of Notch manipula-
tions on BMP pathway activation, we determined nuclear
pSMAD1/5 levels on exposure of HUVEC to different amounts
of ligand. A twofold serial dose–response curve to BMP6 yielded a
prototypical sigmoidal semi-log curve for BMP-mediated EC
activation, as measured by nuclear pSMAD1/5 levels
(Supplementary Fig. 2a,b). We next tested the effect of Notch
activation by plating HUVEC onto Fc-conjugated Dll4 ligand
(Dll4-Fc) before short-term treatment with BMP6 and found that
the EC50 for BMP-mediated EC activation increased significantly
compared with controls (Fig. 2m). We confirmed, using inducible
NICD expression in HUVEC, that elevated Notch signalling
increased the EC50 (Supplementary Fig. 2c). This relationship also
held at the single-cell level, as EC expressing NICD had reduced
levels of pSMAD1/5 (Fig. 2n,o). Conversely, HUVEC treated with
siRNA targeting Notch1 (Supplementary Figs 2d and 5c) were
more sensitive to lower concentrations of BMP6 relative to
controls (Supplementary Fig. 2e) and they exhibited increased
branching with equivalent BMP6 stimulation (Supplementary
Fig. 2f–j). The results of in vivo and in vitro Notch manipulations
support our hypothesis that Notch regulates the innate BMP
responsiveness of EC, and that the increased BMP responsiveness
of EC with low Notch signalling promotes lateral branching.
SMAD6 integrates Notch and pro-angiogenic BMP responsiveness.
Notch regulates VEGF signalling by modulating levels of VEGF
receptor RNAs34,35. Therefore, we reasoned that Notch would
regulate BMP responsiveness via expression of BMP receptors.
Surprisingly, we detected no significant changes in expression
levels of several type I and type II BMP receptors after Notch
stimulation of HUVEC via Dll4-Fc plating or Notch blockade via
DAPT (Supplementary Fig. 3a,b). BMP signalling is also
intrinsically regulated by an intracellular inhibitory protein,
SMAD6 (refs 17,18,36,37) and SMAD6 messenger RNA levels
increased with Notch stimulation and decreased with Notch
blockade in HUVEC (Fig. 3a). This relationship was maintained
at the single-cell level, as EC expressing NICD had elevated levels
of SMAD6 protein (Fig. 3b,c). In other cell types, SMAD6 inhibits
BMP signalling by preventing R-SMAD phosphorylation and
nuclear localization17,18, but its activity in EC and effects on
angiogenesis are unknown. Therefore, we generated HUVEC
expressing doxycycline-inducible SMAD6 fused to tdTomato.
The tagged SMAD6 protein reacted with a SMAD6 antibody by
immunofluorescence (Supplementary Fig. 3c–f) and suppressed
nuclear pSMAD1/5 levels in HUVEC in a cell autonomous and
dose-dependent manner (Fig. 3d,e). Conversely, reduction of
SMAD6 protein levels via siRNA knockdown (Supplementary
Figs 3g and 5d) increased BMP6-induced nuclear pSMAD1/5
(Fig. 3f). These findings show that an intrinsic BMP pathway
inhibitor, SMAD6, modulates BMP signalling in EC. As elevated
pSMAD levels were associated with increased lateral branching
and SMAD6 suppressed BMP signalling, we hypothesized that
loss of SMAD6 would increase BMP responsiveness of EC and
promote branching. Consistent with this hypothesis, reduced
SMAD6 levels via siRNA significantly increased branching of
sprouting HUVEC with added exogenous BMP6 (Fig. 3g–k).
These results show that SMAD6 regulates angiogenesis, probably
by intrinsically modulating the magnitude of EC responses to
BMP inputs.
To determine the functional relevance of SMAD6 in vivo, we
first examined expression by fluorescence-activated cell sorting
(FACS) in EC from zebrafish embryos that expressed the Notch
signalling reporter (Fig. 2a). Zebrafish have two SMAD6
orthologues, smad6a and smad6b. We assessed expression of
smad6b in EC in vivo, because its sequence is more homologous
to that of human SMAD6. EC sorted for high levels of Notch
reporter signalling had significantly elevated levels of RNAs that
are expected to be elevated in arterial Notch-positive EC such as
notch1b and ephrinb2. They also had significantly elevated levels
of smad6b RNA relative to EC sorted from the same embryos
with little or no Notch reporter signalling (Fig. 4a). We
next manipulated embryonic SMAD6 expression. As global
manipulations of smad6b are predicted to profoundly perturb
dorsal–ventral axis formation in zebrafish embryos38, we used the
Tol2 system to generate F0 mosaic embryos expressing green
fluorescent protein (GFP)-tagged smad6b, or GFP alone, under
control of the vascular-specific fli1 promoter. We predicted that
Smad6b expression would preferentially affect BMP-responsive
EC with low Notch levels, such as those in the cardinal vein and
the CVP. EC expressing Smad6b-eGFP were significantly reduced
in the cardinal vein and CVP, and enriched in the DA and ISVs,
compared with EC expressing only GFP (Fig. 4b–d), consistent
with our finding that Smad6b expression is elevated in EC of
embryos with high Notch signalling reporter expression,
presumably including EC from the DA and ISVs. These
findings suggest that forced Smad6b expression prevents EC
from colonizing the vein and CVP where Notch signalling is low,
but is irrelevant in arterial EC where Notch signalling is relatively
high and support a role for SMAD6 in angiogenesis in vivo.
We next asked whether reduced levels of smad6b affect blood
vessel branching and predicted that if SMAD6 is important for
Notch-mediated effects in vivo, its reduction would more
profoundly affect Notch-dependent ISV sprouting that is
normally refractory to BMP9. To overcome the effects of global
smad6b manipulations on dorsal–ventral axis formation, we
developed a tissue-specific mRNA knockdown system for
zebrafish based on a CRISPRi strategy39–42. However, CRISPRi
is poorly efficient in eukaryotic cells40; thus, dCas9 was fused to
the Drosophila engrailed repressor domain43 to generate dCas9-
Engrailed Repressor domain (EnR), a chimeric transcriptional
repressor protein that is targeted by short guide (sg) RNAs. We
validated the efficacy of dCas9-EnR in global knockdown using
sgRNAs targeting bmp6 or smad6b and observed the expected
dorsalization (bmp6 loss-of-function) or ventralization (smad6b
loss-of-function) phenotypes (Supplementary Fig. 4a–d). We also
validated sgRNA effects at the mRNA level by quantitative
reverse transcriptase–PCR (qRT–PCR) for the targeted genes
(Supplementary Fig. 4e). Next, transgenic embryos expressing a
fli1 promoter-driven dCas9-EnR were generated using the Tol2
system. F1 embryos expressing vascular restricted dCas9-EnR
were indistinguishable from wild-type (WT) siblings and
dCas9-EnR mRNA expression was confirmed by RT–PCR
(Supplementary Figs 4f–h anf 5e). To determine whether
Smad6b regulates BMP responsiveness in vivo, we injected
sgRNAs targeting smad6b into Tg(fli1:dCas9-EnR);Tg(hsp701:
bmp2b);Tg(kdrl:GFP) embryos, then heat shocked to induce
ectopic Bmp2b expression at 26 hpf, well beyond the early
developmental window leading to axis defects. WT heat-shocked
embryos without sgRNAs had normal ISV formation
(Supplementary Fig. 4i,j,m). Likewise, Tg(fli:dCas9-EnR);Tg(kdrl:GFP)
embryos injected with scrambled sgRNAs or smad6b sgRNAs and
heat-shocked had normal ISV formation (Fig. 4e,f,i). Heat-shock
induction of Bmp2b expression did not perturb axis formation,
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but induced some ectopic ISV formation in controls and
Tg(fli:dCas9-EnR); Tg(hsp701:bmp2b);Tg(kdrl:GFP) embryos
injected with scrambled sgRNAs (Fig. 4g,i and Supplementary
Fig. 4k,m). However, the frequency of ectopic ISV formation
significantly increased in transgenic embryos overexpressing
Bmp2b and injected with smad6b sgRNAs (Fig. 4h,i; Supplemen-
tary Fig. 4l,m). Remarkably, the phenotype of BMP-overexpressing,
vascular smad6b knockdown embryos resembles that of BMP-
overexpressing embryos with reduced Notch signalling. Combined,
these in vivo results support a model whereby SMAD6 represses
BMP responsiveness and vessel branching.
Based on the similarity of phenotypes in vivo and the Notch
responsiveness of SMAD6 RNA and protein in EC, we further
explored the mechanism by which Notch regulates SMAD6 gene
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Student’s t-test. (g–j) HUVEC 3D sprouting assay with indicated siRNAs and treatment, visualized with phalloidin (actin) and depth-encoded in a
compressed z-stack, representative of three independent experiments. (k) Quantification of branching (n¼ 11 NT/control, 13 NT/BMP6, 12 SMAD6
siRNA/control and 11 SMAD6 siRNA/BMP6 beads). Data points, individual beads; bars, mean±95% CI. **Pr0.01 and ***Pr0.001 by Kruskal–Wallis with
Dunn’s post-hoc test.
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expression. Analysis of the SMAD6 50-promoter region revealed a
consensus sequence for Recombination Signal Binding Protein for
Immunoglobulin Kappa J Region (RBPJ) binding to DNA, which is
required for Notch-dependent transcription in cells. A chromatin
immunoprecipitation (ChIP) assay using two separate antibodies
to RBPJ revealed that RBPJ binds at the identified site in the
SMAD6 promoter (Fig. 5a and Supplementary Fig. 5a), suggesting
that Notch directly regulates transcription of SMAD6 RNA.
Finally, we hypothesized that SMAD6 is functionally down-
stream of Notch in regulating the BMP responsiveness of EC. We
tested this hypothesis by activating Notch in HUVEC with
reduced levels of SMAD6, and we assessed BMP pathway
signalling via nuclear localization of pSMAD1/5. Short-term
BMP6 treatment of HUVEC led to elevated nuclear pSMAD
levels that were significantly suppressed by Notch stimulation
(Fig. 5b,c,f,g,j). In contrast, HUVEC with reduced SMAD6 levels
and BMP6 stimulation did not respond to Notch stimulation with
suppression of SMAD1/5 activation, but had nuclear pSMAD1/5
levels equivalent to that of HUVEC without Notch stimulation
(Fig. 5d,e,h–j). These data indicate that SMAD6 is functionally
downstream of Notch and is required to mediate the effects of
Notch on BMP responsiveness in EC.
Discussion
Collectively, our data support a model whereby pro-angiogenic
BMPs increase vascular complexity through regulation of lateral
branching. The magnitude of intrinsic BMP responsiveness in EC
is modulated by Notch-mediated regulation of the BMP inhibitor
SMAD6 to ‘tune’ BMP responsiveness (Fig. 6), and combined
effects on branch frequency and angle lead to a more arborized or
‘bush-like’ vascular network as BMP ligand levels increase. In this
model, Notch signalling sets levels of SMAD6 in a given EC and
SMAD6 levels regulate the amount of pSMAD1/5 that translo-
cates to the nucleus with a given input of BMP ligand. As ligand
levels increase, more EC reach a threshold that allows them to
assume a tip cell phenotype and sprout to form a new branch.
This includes a subset of EC in a classic ‘stalk’ position, and our
finding of differential BMP responsiveness in the stalk cell
compartment indicates dissimilarity among stalk cells. Notch is a
major regulator of the tip cell versus stalk cell phenotype in EC of
angiogenic sprouts26,44, and we now propose that Notch also
differentiates stalk cells by modulating expression of SMAD6. We
predict that Notch-dependent changes in SMAD6 expression
among dynamically competing sprouting EC shifts BMP
responsiveness relative to a threshold necessary for lateral
branching. Subsequently, as arteries reach homeostasis and
Notch signalling becomes more uniform, these changes may
lead to more uniform SMAD6 levels and overall dampened BMP
responsiveness in arteries versus veins.
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Figure 4 | SMAD6 regulates BMP-dependent angiogenesis in vivo.
(a) Quantitative RT–PCR for indicated genes, fold-change Notch
reporterþ (NRþ )/Notch reporter- (NR-) EC, relative to e1fa. Error bars,
mean±s.e.m., N¼ 5 replicates; one-sample Student’s T-test, **Pr0.01 and
***Pr0.001. (b–d) F0 mosaic transgenic zebrafish embryos (44 hpf)
expressing GFP control (b) or GFP-tagged smad6b (c) from the
vessel-specific fli promoter in the Tg(kdrl:mCherry) line. Arrows, GFPþ EC.
(d) Arterial versus venous distribution of GFPþ EC quantified as
percentage of total GFPþ EC on a per-embryo basis. Data bars, average
per cent arterial and venous GFPþ EC, ±95% CI, representative of three
independent experiments (n¼ 18 fli:GFP and 30 fli:smad6b-GFP F0
embryos). ****Pr0.0001 by w2 analysis (1 degree of freedom).
(e–h) Heat-shocked F1 embryos (heat shock at 26 hpf, analysed at
44–46 hpf) from Tg(fli:dCas9-EnR) and Tg(hsp70l:bmp2b;Tg(kdrl:GFP)
crosses, injected with scrambled (scram) or with smad6b sgRNAs. Arrows,
ectopic ISV sprouts. (g,h) have Z-planes with ectopic venous sprouts
removed. (i) Quantification of arterial vascular defects (% segments
with ectopic ISVs) in heat-shocked embryos of indicated genotypes,
representative of two independent experiments (scram, n¼4; smad6,
n¼6; scram/hsbmp, n¼4; smad6/hsbmp, n¼ 5). Error bars,
mean±s.e.m.; *Pr0.05 and ****Pr0.0001 by one-way analysis of
variance, with Tukey’s post-hoc test.
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Allthough convergence of Notch and BMP pathways at
downstream target genes has been described8,13,30, our data
strongly suggest that intrinsic responsiveness to BMP signals is
independently preset by Notch to regulate lateral branching.
Recent work suggests that Notch also maintains the stalk
cell phenotype via downregulation of Neuropilin-1 (ref. 45).
Low Neuropilin-1 in stalk cells relieves inhibition of ALK1 and
ALK5, and promotes tranforming growth factor-b-mediated
pSMAD2/3 signalling to maintain the stalk cell phenotype. Our
work shows that SMAD6, a Notch-regulated cell-intrinsic BMP
pathway inhibitor, modulates EC responses to pro-angiogenic
BMP ligands that stimulate pSMAD1/5 signalling and a tip cell
phenotype. Thus, Notch-mediated SMAD6 regulation ‘tunes’
branching responses to BMP ligands among stalk cells and
coordinately regulates the magnitude of BMP pathway activation
and sprouting, to determine the patterning of growing vessel
networks.
Methods
Cell maintenance and processing. No cell lines used in this study are found in
the International cell line authentication committee (ICLAC) commonly
misidentified cell line database.
Mouse ES cells were maintained and differentiated as previously described46.
Briefly, cells were maintained undifferentiated by culture in DMEM media
supplemented with conditioned media from 5,637 human bladder cancer cells
(ATCC HTB9) and passaged at 2–4 days. For differentiation, ES cells aged for
2–4 days beyond passage were trypsinized, resuspended and inoculated into
droplets on a tissue culture plate lid. The lid was inverted, hanging drops cultured
for 2 days to generate embryoid bodies (EBs), then inverted again and flushed with
media. After culture in a new plate for 1 day, EBs were seeded at 20–30 EBs per
well of a 24-well plate and differentiated in DMEM, Hi-glucose, 20% FCS, 150 mM
monothioglycerol and 50 mgml 1 gentamicin. Media was changed every 2 days
until fixation. Human BMP2 (R&D Systems 355-BEC) was added at d6 and d7 at
200 ngml 1. Day 8 cultures were rinsed with 1 PBS and fixed for 5min in
ice-cold methanol-acetone (50:50)47. Following 6 5min washes in 1 PBS,
cultures were stained with rat anti-mouse PECAM-1 (BD Biosciences 553370) at
1:1,000 and then goat anti-rat IgG Alexa Fluor 488 (Life Technologies A-11006)
at 1:2,000 overnight at 4 C in Staining Solution (Jackson ImmunoResearch
005-000-121), 5% goat serum, 1% BSA and 0.3% TritonX-100 in DPBS (Fisher
MT-21-031-CV).
HUVEC (Lonza C2519A) were maintained as per the manufacturer’s
recommendations and were used in experiments from passages 2 to 5. All
experiments were independently replicated using two distinct lots of HUVEC.
HUVEC were certified mycoplasma-free by the UNC Tissue Culture Facility.
Normal Human Lung Fibroblasts (NHLF; Lonza CC-2512) were maintained as per
the manufacturer’s recommendations. NHLF were certified mycoplasma-free by
the UNC Tissue Culture Facility.
To induce Notch signalling, HUVEC were grown on recombinant protein G
(Life Technologies 10–1201)-immobilized 10 mgml 1 Fc-Dll4 (Adipogen
AG-40A-0077-C050)48 (or 10 mgml 1 Fc-IgG control (Life Technologies
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Figure 5 | SMAD6 mediates Notch-dependent suppression of BMP signalling. (a) ChIP assay on micrococcal nuclease-digested HUVEC DNA
immunoprecipitated with indicated antibodies and amplified unique primers targeting a single putative RBPJ consensus sequence in the SMAD6 promoter.
Left, size marker (bp). (b–i) HUVEC transfected with non-targeting (b,c,f,g) or SMAD6 siRNA (d,e,h,i), plated onto IgG (b,d,f,h) or Dll4-Fc (c,e,g,i), then
treated with control (b–e) or 50 ngml 1 BMP6 (f–i) for 90min before staining for nuclear pSMAD1/5. Scale bar, 10mm. (j) Quantification of nuclear
pSMAD1/5 fluorescence intensity, representative of three independent experiments. Data points, individual nuclei (n indicated on graph); bars,
mean±95% CI. *Pr0.05, **Pr0.01 and ****Pr0.0001 by Kruskal–Wallis with Dunn’s post-hoc test.
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10374-H02H-50)) for 24 h, with BMP6 treatments and immunostaining performed
as described above. For doxycycline induction, stably infected HUVEC
FLAG-NICD cells or controls (see below) were treated for 24 h with 1–2 ngml 1
doxycycline (Sigma-Aldrich D9891-1G) in growth media, then incubated with
BMP6 (200 ngml 1) for 2 h, fixed in 4% paraformaldehyde (PFA) for 15min,
rinsed three times with PBS, permeabilized with 0.5% Triton-X for 20min and then
blocked overnight with 1% BSA/0.3% Triton-X/5% goat serum in PBS.
Sprouting angiogenesis assay. The 3D sprouting angiogenesis assay was per-
formed as previously described21. Briefly, 1–2 106 HUVEC were mixed with
100ml of a 60,000ml 1 suspension of cytodex beads (GE Healthcare 17-0485-01)
in 5ml HUVEC growth media (EBM-2þ EGM-2 BulletKit, Lonza CC-3156 and
CC-3162, respectively), maintained in suspension for 4 h by mixing every 15min,
then placed in 60mm dishes at 37 C overnight. Beads were recovered from the
plate by gentle rinsing and washed 3 in HUVEC growth media, then
resuspended in 10ml of 2mgml 1 fibrinogen/0.15 Uml 1 aprotinin. Five
microlitres of a 50Uml 1 thrombin solution was added to each well of a 24-well
plate, followed by gently mixing in 500 ml of HUVEC-coated beads in fibrinogen/
aprotinin per well. After 5min atRT, the plate was transferred to 37 C for 30min
for polymerization, then 1ml of 20,000 cells ml 1 NHLF was added to each well.
Media was refreshed every 2 days until fixation. Recombinant human BMP2 or
BMP6 (R&D Systems #355-BM-010 or #507-BP-020, respectively) were added at
d2–6 at 200 ng ml 1. Day 7 cultures were fixed in 2% PFA (Electron Microscopy
Supplies #15713) in DPBS (Fisher #MT-21-031-CV) for 30m, then stained with
Alexa Fluor 488 Phalloidin or Alexa Fluor 594 Phalloidin (Life Technologies
#A12379 or #A12381, respectively) overnight at 4 C at 1:100 in Staining Solution
(5% Goat Serum (Jackson ImmunoResearch #005-000-121), 1% BSA, and 0.3%
TritonX-100 in DPBS). Nuclei were counterstained with DRAQ7 (Abcam
#ab109202) for 5min at 1:1,000 in DPBS.
Immunofluorescence. For pSMAD1/5 immunofluorescence, HUVEC were grown
for 24 h on 0.1% gelatin (Sigma-Aldrich #G9136-10MG) coated 12mm diameter
#1.5 glass coverslips (Fisher #12-545-81). HUVEC were pretreated for 4 h in
OptiMEM (Life Technologies #31985-070)þ 0.1% normal bovine calf serum
(NBCS), then treated for 90min with BMP6 at the doses described in each figure.
Cells were fixed for 10min in 4% PFA/DPBS, followed by permeabilization in 0.5%
Triton-X 100/DPBS. Cells were blocked in staining solution for 1 h, followed by
overnight incubation at 4 C with Rabbit anti-pSMAD1/5 (R&D) at 1:1,000 in
staining solution (see Supplementary Table 1 for antibodies and concentrations).
Goat anti-Rabbit Alexa Fluor 488 secondary antibody was added at 1:1,000 in
staining solution for 2 h at room temperature (RT). For FLAG experiments,
HUVEC were incubated with 1:1,000 a-pSMAD 1/5 antibody (R&D) and 1:5,000
a-FLAG antibody (Sigma) overnight, then washed and incubated with 1:500 Alexa
Fluor 594 to detect pSMAD 1/5 and with 1:5,000 Alexa Fluor 488 to detect FLAG.
DRAQ7 (1:1,000) was used to visualize the nucleus. Coverslips were mounted onto
slides in ProLong Diamond Antifade Mountant (Life Technologies P36961).
For SMAD6 staining, HUVEC were incubated in 1:100 a-SMAD6 (Abcam) and
1:5,000 a-FLAG antibody (Sigma) overnight, and then with 1:500 Alexa Fluor 594
to detect SMAD6 and with 1:5,000 Alexa Fluor 488 to detect the FLAG antibody.
Alexa Fluor 647-conjugated Phalloidin was used to visualize cell boundaries.
Plasmids. To generate a lentiviral vector expressing human SMAD6-tdTomato
fusion protein under the control of a doxycycline-inducible promoter, the
full-length human SMAD6 coding sequence was amplified from pOTB7 hSMAD6
(GE Dharmacon MHS6278–202829590) using PrimeSTAR MAX polymerase
(Clontech R045A) and the following primers:
Forward: 50-ATTCACAGATCTGCCACCATGTTCAGGTCCAAACGCTCG-30 ,
containing 6 nt overhang, BglII restriction site and Kozak consensus sequence,
Reverse: 50-ATTCACGGTACCCTTCTGGGGTTGTTGAGGAGGATCTC-30 ,
containing 6 nt overhang, KpnI restriction site and 1 nt deletion from stop codon
for in-frame read-through to carboxy-terminal tdTomato tag.
PCR product was purified using NucleoSpin kit (Clontech 740609) and
double-digested for 10min at 37 with BglII and KpnI (Life Technologies FD0084
and FD0524, respectively). ptdTomato-N1 empty vector (Clontech 632532) was
double-digested in parallel using the same enzymes and de-phosphorylated
for 5min at 37 using FastAP Thermosensitive Alkaline Phosphatase (Life
Technologies EF0654). Products were ligated at a 3:1 (Insert:Vector) molar ratio for
10min at RT using T4 Rapid Ligation Kit (Life Technologies K1422), followed by
transformation, selection, plasmid purification and sequencing, to verify the fidelity
of the insert.
The full-length hSMAD6-tdTomato chimera was PCR-amplified and cloned
into gateway-compatible pME-MCS49 from the newly generated template using a
similar strategy.
Forward primer: 50-ATTCACAAGCTTGCCACCATGTTCAGGTCCAAACGC
TCG-30 , containing 6 nt overhang, HindIII (Life Technologies FD0504) restriction
site and Kozak consensus sequence,
Reverse primer: 50-ATTCACTCTAGACTACTTGTACAGCTCGTCCAT-30 ,
containing 6 nt overhang and XbaI (Life Technologies FD0684) restriction site.
An LR reaction was performed using Clonase II Plus (Life Technologies
12538-120), pME-hSAMD6-tdTomato and pLIX-402 EV (a gift from David Root
(Addgene plasmid 41394)) to generate pLIX-402 hSMAD6-tdTomato.
pLIX-402 3 -FLAG-mN1ICD was generated from pCMV-7 3 -FLAG
mN1ICD50 (a gift from Raphael Kopan, Addgene plasmid 20183) by double
digestion and ligation into pME-MCS as described above, using FastDigest EcoRI
and BamHI (Life Technologies FD0274 and FD0054, respectively), followed by an
LR reaction.
Zebrafish transgenesis was performed using the Tol2 system49. To generate the
pTol2 fli1:smad6b-GFP;cmlc2:GFP targeting vector, full-length smad6b was
amplified from a 24 hpf embryo complementary DNA library using PrimeSTAR
Max and cloned into pCS2 FLAG EV (a gift from Peter Klein, Addgene plasmid
16331) as described above, using the following primers:
Forward: 50-ATTCACGGATCCGCCACCATGTTCAGGACGAAACGC
TCA-30, containing a 6 nt overhang, BamHI site and Kozak consensus sequence,
Reverse: 50-ATTCACATCGATATCTGTGGTTGTTGAGGAGG-30 , containing
a 6 nt overhang, ClaI (Life Technologies FD0143) site and 2 nt deletion from the
stop codon to maintain frame with C-terminal tags.
C-terminal FLAG tag was replaced with GFP by amplifying GFP from
peGFP-N1 EV (Clontech 6085-1), digested and ligated as described above, using
the following primers:
Forward: 50-ATTCACATCGATTGGTGAGCAAGGGCGAGGAGC-30 ,
containing a 6 nt overhang, ClaI site and a 1 nt deletion from the start codon,
Reverse: 50-ATTCACAGGCCTTTACTTGTACAGCTCGTCCAT-30 ,
containing a 6 nt overhang and StuI (NEB R0187S) site.
Smad6b-GFP was then ligated into pME-MCS using a BamHI and NotI
(Life Technologies FD0594) double digest as described above. A four-way LR
reaction using p5E-fli1ep (a gift from Nathan Lawson, Addgene plasmid 31160),
pME-smad6b-GFP, p3E-polyA49 and pDEST Tol2 CG2 (ref. 49) produced the final
targeting vector.
To generate the pTol2-fli1ep:Cas9-EnR;cmlc2:GFP targeting vector, dCas9 was
amplified from pdCas9 (ref. 41; a gift from Stanley Qi, Addgene plasmid 44246)
and ligated into pCS2-EnR43 (a gift from Ramesh Shivdasani, Addgene plasmid
11028) using the following primers:
Forward: 50-GGATCCGCCACCATGGACAAGAAGTATTCTATC-30 ,
containing a 6 nt overhang, BamHI site and Kozak consensus sequence,
Reverse: 50-ATTCACATCGATTACCAATGCCGTCTACCTT
TCTCTTCTTTTTTGGATCTACCTTTCTCTTCTTTTTTGGATCTACCTT-30 ,
containing a 6 nt overhang, ClaI site and deletion of the stop codon.
dCas9-EnR was subcloned into pME-MCS using BamHI/XbaI double digests
and four-way LR reaction performed with the same 5E, 3E and DEST vectors
described above.
Lentivirus production and stably infected HUVEC. Lenti-X 293T cells (Clontech
632180) were maintained in DMEM Hi Glucose (Life Technologies 11995-065)
þ 10% normal bovine calf serum (NBCS) according to the manufacturer’s
instructions. For lentiviral production, cells were plated onto 10 cm dishes at
50,000 cm 2. The following morning, cells were co-transfected with 20 mg pLIX
402 vectors (described above) and 6 mg pMD2.G (a gift from Didier Trono,
Addgene plasmid 12259), 5 mg pRSV-REV51 (a gift from Didier Trono, Addgene
plasmid 12253) and 10 mg pMDLg/pRRE51 (a gift from Didier Trono, Addgene
plasmid 12251) using Lipofectamine 2000 (Life Technologies 11668019) according
to the manufacturer’s protocol. Transfection medium was aspirated 8 h later and
6ml fresh medium added. Forty-eight hours later, medium was harvested by
centrifugation, filtered through a sterile 0.22 mm, 30mm PES filter (Fisher Scientific
50-202-062), mixed 1:1 with HUVEC growth media (EBM-2þEGM-2 BulletKit,
Lonza CC-3156 and CC-3162, respectively) and added to 80% confluent p2
HUVEC. The next day, medium was aspirated and fresh medium added. After
72 h, infected HUVEC were selected using 1 ngml 1 puromycin (Sigma-Aldrich
P9620-10ml) in HUVEC growth medium, changed daily, for 2 weeks. Surviving
HUVEC were then trypsinized, re-plated under 0.5 ngml 1 puromycin selection
and expanded.
siRNA transfections. siRNAs used in this study are listed in Supplementary
Table 2. HUVEC were plated at 20,000 cm 2 onto 6 cm dishes. The following day,
B80% confluent HUVEC were transfected with 10 nM siRNA using Lipofectamine
RNAiMax (Life Technologies 13778150) according to the manufacturer’s protocol.
The following day, HUVEC were trypsinized, coated onto Cytodex beads for
3D experiments or plated onto 12mm coverslips for two-dimensional (2D)
experiments and re-transfected with siRNA to ensure maximal knockdown
persisted throughout the duration of the experiments. Residual cells were analysed
by western blotting, to verify knockdown efficacy.
Western blotting. HUVEC whole-cell lysates were prepared in RIPA buffer
supplemented with protease/phosphatase inhibitor cocktail (Cell Signaling 5872S).
Ten micrograms of whole-cell lysates were separated on 10% TGX Stain-Free
FastCast SDS–PAGE gels (Bio-Rad 161–0183), followed by 2min ultraviolet
activation of TGX stain for total protein quantification. Proteins were transferred
to polyvinylidene difluoride membranes (Bio-Rad 162–0177), blots were imaged
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under ultraviolet for total protein, blocked for 2 h in 5% non-fat milk (NFM) in
PBSþ 0.1% Tween20 (PBST), then incubated overnight at 4 C with primary
antibody in 1% NFM in PBST (see Supplementary Table 1 for primary and
secondary antibodies and concentrations). Horseradish peroxidase-conjugated
secondary antibodies (Life Technologies goat anti-rabbit G21234 or rabbit
anti-mouse 816720) were added for 2 h at RT in 1% NFM in PBST. Clarity ECL
(Bio-Rad 170–5060) was used for detection. Films were digitized using an
AlphaImager (ProteinSimple) gel scanning station and band densities calculated in
FIJI52, following established guidelines53.
Quantitative RT–PCR. Primers used in this study are listed in Supplementary
Table 3. mRNA was collected from experimental samples using Trizol reagent
(Life Technologies 15596026). cDNA was generated from 1 mg mRNA using iScript
reverse transcription kit (Bio-Rad 170–8891) and diluted 1:3 in water. qRT–PCR
was performed using iTaq Universal SYBR Green SuperMix (Bio-Rad 172–5121)
on an ABI 7900HT Fast Real-Time PCR System (Life Technologies 4329001).
Threefold serial dilutions of pooled cDNA were used to generate standard curves
for each amplicon and data were analysed via the Pfaffl method54.
RNA was isolated from FACS-enriched zebrafish cells using RNA-easy Micro
Plus kit (Qiagen) and reverse transcribed with Invitrogen’s Superscript III
First-Strand Synthesis Supermix (Invitrogen) according to the manufacturer’s
instructions. For qRT–PCR, NCBI’s Primer-BLAST was used to design
exon-spanning, gene-specific SybrGreen primers (see Supplementary Table 3).
All primers were validated by high-resolution melt analysis, size confirmation
and no-template controls. SybrGreen real-time PCR was performed in triplicate
on the Viia7 real-time PCR system (Invitrogen). For quantification, the
DDCT method was used where raw CT values were normalized to elongation
factor alpha (eef1a1l1) and paired sorting control, then calculated fold
change as 2(DDCT). Statistical significance was determined by one-sample T-test
comparing with a reference value of onefold change.
Zebrafish. Zebrafish (Danio rerio) embryos were maintained as previously
described9. The following transgenic lines were used: Tg(kdrl:GFP)s843 (ref. 55),
Tg(kdrl:mCherry) (gift of D. Stainier), Tg(hsp70l:bmp2b)fr13 (ref. 56),
Tg(Tp1bglob:eGFP)um14 (ref. 57), Tg(UAS:myc-Notch1a-intra)kca3 and
Tg(hsp70l:Gal4)1.5kca4 (ref. 58), and Tg(fli1ep:dCas9-EnR;cmlc2:GFP) (this study).
For all microinjections, one-cell-stage embryos were dechorionated using
20mgml 1 (W/V in ddH2O) pronase (Sigma P6911), then rinsed repeatedly
using a total of 1 l H Buffer (60mM NaCl, 2.3mM NaHCO3, 1.1mM CaCl2 and
0.67mM KCl).
For Notch inhibition, embryos were treated with DAPT at 100 mM, sonicated in
1% dimethyl sulfoxide/1 1-phenyl 2-thiourea (PTU)/E3, or in 1% dimethyl
sulfoxide/1 1-phenyl 2-thiourea (PTU)/E3 control, from 10 hpf until harvest. For
Notch or BMP activation, embryos were heat-shocked at 26 hpf for 30min at 40 C
or kept as unheat-shocked controls. For transgenesis, capped mRNA was generated
from pCS2 FA Transposase49 using the T7 mMessage mMachine in vitro synthesis
kit (Life Technologies AM1344). Five picograms each of transposase mRNA and
Tol2 vector were injected into the cell of dechorionated one-cell-stage zebrafish
embryos from AB (fli1ep:dCas9-EnR;cmlc2:GFP) or Tg(kdrl:mCherry
(fli1ep:smad6b-GFP;cmlc2:GFP), or fli1ep:GFP;cmlc2:GFP) in-crosses. Embryos
were screened for cardiac GFP expression (transgenesis) and raised until harvest as
F0 mosaics (fli1ep:smad6b-GFP or fli1ep:GFP) or raised to adulthood and screened
for germline transmission (fli1ep:dCas9-EnR;cmlc2:GFP).
For global CRISPRi, WT embryos from AB parents were injected at the one-cell
stage with 450 pg dCas9-EnR mRNA alone or in conjunction with 200 pg
gene-targeting sgRNA. Embryos were analysed at 24 hpf for gross dorsal–ventral
patterning defects consistent with early BMP manipulations38. For CRISPRi, 450
embryos from Tg(hsp:bmp2b);Tg(kdrl:GFP)  Tg(fli1ep:dCas9-EnR;cmlc2:GFP)
crosses were injected using a PicoSpritzer III positive pressure micro-injection
apparatus at the one-cell-stage with 200 pg (in 1 nl) of scrambled (scram) or
smad6b-targeting sgRNAs. Embryos were raised at 28 C in 1 E3 and heat-
shocked to overexpress Bmp2b at 26 hpf as described above. Embryos were fixed
and imaged on an FV1200 confocal microscope at 44 hpf. sgRNA sequences used
are listed in Supplementary Table 3.
For all zebrafish experiments, embryos were collected and sorted into
treatments blindly with respect to genotype, to ensure appropriate randomization.
For all experiments, any embryos that failed to gastrulate or exhibited severe
developmental patterning defects were excluded from analysis. All animals are
maintained in an institutional animal care and use committee (IACUC)-approved
satellite facility according to public health service (PHS) policy on Humane Care
and Use of Laboratory Animals.
FACS sorting. Staged fish embryos were obtained by breeding hemizygous
Tg(Tp1:EGFP);Tg(myl7:dsRed) adult zebrafish with homozygous Tg(fli1:tdTomato;
cmlc2:GFP) fish by group spawning methods. Non-transgenic embryos (for use in
setting FACS gates) were obtained by inbreeding WT (Tubingen) fish. Embryos
from individual spawning groups were pooled into single clutch biological
replicates. At 26 hpf, embryos were manually sorted for Tp1:EGFP expression.
At 28–32 hpf, embryos were prepared for FACS sorting as previously described19.
Briefly, embryos were manually dechorinated, yolk removed, then dissociated into
single-cell suspension using a combination of TrypLE (Gibco) and FACSMax
(Gentlantis). Cells were re-suspended in ice-cold L-15 (Gibco) supplemented with
5% heat-inactivated FBS (Hyclone), passed through 40 and 35 mm filters, then
counterstained with Live/Dead fixable near-IR stain (Molecular Probes). A SH800
cell sorter (Sony) was used to sort live, tdTomatoþ cells by Tp1:EGFP expression
level and harvested directly into RTL lysis buffer, then stored at  20 for later RNA
purification.
ChIP assay. HUVEC were plated on 100mm culture dishes and grown for 24 h
and native protein–DNA complexes were cross-linked by treatment with 1% for-
maldehyde for 15min. Simple ChIP Plus Enzymatic Chromatin IP kit
(Cell Signaling 9005) was used per the manufacturer’s protocol. Briefly, equal
aliquots of isolated chromatin were subjected to immunoprecipitation with
anti-RBPJ antibodies (Cell Signaling 5313s, Abcam ab25949) or rabbit IgG control
at 2 mg per 500 ml. PCR reactions of immunoprecipitated DNA were performed to
validate RBPJ binding on the Smad6 promoter. PCR primers used:
2: FWD: 50-ATTAGCCGGGCATAGTGGTGCAT-30
REV: 50-TGCACTCAAGTGATTCTCGTGCCT-30
3: FWD: 50-AGGCGGATCACTTCAGGCAGGTCA-30
REV: 50-GCTCTGCACTCAAGTGATTCTCGT-30.
PCR products were separated by gel electrophoresis and visualized by SYBRsafe
(Invitrogen).
Imaging and quantification. All images were acquired on an Olympus FluoView
FV1200 confocal microscope, equipped with Green, Red and Far-Red lasers and
detectors. Olympus OIB file formats were imported into FIJI using Bio-Formats
Importer20 for analysis and quantification, as described below.
Branch frequency was measured by skeletonizing ES-cell-derived vessels or
HUVEC-derived 3D sprouting angiogenesis assay vessels and calculating branches
per mm using Image J (NIH). For branching parameters, the sprout length was
measured from the base of the spout to the most distal end. The maximum branch
angle was calculated at sprout junctions, excluding branches that fused with other
sprouts distal to the junction. The percentage of tip cells was quantified in all multi-
nucleated sprouts. Tip cells were defined as the cell nucleus located most distal in a
sprout. In zebrafish, the percentage of somites containing angiogenic sprouts was
calculated. The first 12 segments from the end of yolk extension were analysed as
described9.
pSMAD1/5 fluorescence intensities were determined on a single-cell basis in 2D
using FIJI as follows: HUVEC were stained for pSMAD1/5 (also FLAG if relevant)
and incubated with DRAQ7 as described in detail above. The brightest slice in the
DRAQ7 (nuclear) channel from confocal z-stack images was threshold adjusted
into a binary image (black nuclei, white everywhere else). Next, using the ‘Analysis’
- ‘Set Measurements’ menu, analysis was re-directed from the binary nuclear
image to the pSMAD1/5 channel and ‘Analyze’- ‘Analyze Particles’ function was
used with area cutoffs of 50–500 mm2 to return mean grey values per nucleus.
pSMAD1/5 fluorescence intensities were determined on a single-cell basis in 3D
using FIJI as follows: pSMAD1/5 and DRAQ7 (nuclear) channels were
independently compressed along the z axis by summing slices. DRAQ7 channel
was threshold adjusted as described above and binary image used to re-direct
measurements to the pSMAD1/5 channel as described above. The geodesic distance
from the tip nucleus was measured along the length of the vessel from the most
distal portion of the tip nucleus. For tip-cell distance:pSMAD1/5 fluorescence
correlations, both distance and fluorescence were determined relative to the tip cell
(0 mm distance and 100% fluorescence).
SMAD6 fluorescence intensities were determined on a single-cell basis in 2D as
follows: HUVEC were stained for SMAD6 and FLAG, and incubated with
Phalloidin to visualize cell boundaries as described in detail above. SMAD6
fluorescence intensity was measured by finding the brightest slice in the phalloidin
channel, outlining individual cells and calculating integrated density within the
SMAD6 channel with subtraction of background.
Statistics. All statistical analyses were performed using Prism v6.05
(www.graphpad.com), with an a of 0.05. Data were tested for normal distribution
using the D’Agostino and Pearson omnibus normality test within Prism.
For two-sample data sets with equal variances (control -v- a single experimental
condition) unpaired, two-tailed Student’s t-test was used as reported in figure
legends. For data sets with greater than two conditions and equal variances,
one-way analysis of variance with Tukey’s post-hoc test was used as reported
in figure legends. For data sets with greater than two conditions and unequal
variances, Kruskal–Wallis with Dunn’s post-hoc test was used as reported in figure
legends. No a priori sample-size power analyses were performed.
Data availability. Data supporting the findings of this work are available within
the article and its Supplementary Information files, and from the corresponding
author on reasonable request.
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